AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13.
ByAinvest
Monday, Aug 4, 2025 8:05 am ET1min read
• ARS Pharmaceuticals reports Q2 2025 financial results on August 13, 2025. • Webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET. • Dial-in information available upon registration. • Webcast and slides available on the company's website. • Replay available for 30 days following the event. • ARS Pharma focuses on allergic reactions and anaphylaxis prevention.
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) has announced that it will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. The event will provide investors and financial professionals with an opportunity to gain insights into the company's performance and strategic direction.The webcast and conference call will be accessible to participants who register for the event. Dial-in information for conference participants will be available upon registration. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days following the event.
ARS Pharmaceuticals focuses on empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater.
Investor and media contacts for ARS Pharmaceuticals are available for further information. Justin Chakma, ARS Pharma, can be reached at justinc@ars-pharma.com, and Monique Allaire, THRUST, at monique@thrustsc.com. Media inquiries can be directed to Christy Curran, Sam Brown Inc., at christycurran@sambrown.com or 615.414.8668.
For more information about ARS Pharmaceuticals, please visit their website at www.ars-pharma.com.
References:
[1] https://www.marketscreener.com/news/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-second-quarter-2025-financial-resu-ce7c5edadc8bf021
[2] https://www.stocktitan.net/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-m6rhk0b5n521.html
[3] https://finance.yahoo.com/quote/SPRY/
[4] https://investors.idexcorp.com/news-releases/news-release-details/idex-reports-second-quarter-results-0
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet